Organic Aesthetics London

Non-invasive solutions in cancer

At Organic Aesthetics London, we offer leading blood-based diagnostics that can detect cancer early, and track the progression of the disease or its recurrence.

Get in touch today to discuss screening options with one of our Practitioners.


Our Practitioner shall be able to signpost you to our partners and services available.

What is the key to successful cancer treatment?


Timely identification of cancer is crucial for improving treatment outcomes and overall survival. A significant number of cancers remain asymptomatic until reaching advanced stages, where treatment options become limited, often resulting in fatal consequences.


Given the unique nature of each cancer and patient, it’s impractical for treatments to follow a one-size-fits-all approach. Cancer cells can sometimes resist and persist through standard treatments, leading to inadequate responses. A comprehensive understanding of the genetic and cellular composition of your specific cancer can aid in devising a personalized treatment strategy.


Maximize your chances of overcoming cancer by employing a strategic blend of therapy guidance based on a thorough multi-analyte analysis of cancer cells.

Understanding the science


Presently, liquid biopsy plays a crucial role in identifying and handling cancer. Our researchers have devised distinctive, non-intrusive tests that analyze molecular biomarkers and Circulating Tumor Cells (CTCs), transforming personalized cancer management through liquid biopsy into a tangible outcome. 


These tests enable the exploration of molecularly targeted therapies and the customization of treatments, taking into account tumor heterogeneity and the dynamic nature of tumor biology.

Transforming cancer care with a single blood draw through groundbreaking tests


Non-Invasive Cancer Screening for Asymptomatic Individuals


No Risk
Blood Based

Therapy Guidance

Personalized Treatment
for Advanced Cancer


Keeping Track of Cancer
or Its Recurrence
or Changes

Book a Consultation

Looking for more information or wish to discuss Genetic and Cancer Screening service options suitable for you, then why not book a consultation with a member of our consultant practitioners.


Our practitioners will guide you through any questions or queries you may have about our treatments or services.

With Organic Aesthetics you are in safe hands at every step of your treatment journey with us.

Included in our package pricing

Our Cancer Screening Packages include:

Initial Consultation

Post Results Consultation

Onward referral letter


Overview of Tests

Pre-Diagnosis Services

A Breakthrough Non-Invasive Blood Based Test 

That Can Detect Multiple Cancers at Early Stages in Asymptomatic Individuals With High Accuracy to Save Lives and Preserve Quality of Life.

 Available in Trucheck – Intelli for early detection of multiple cancers in asymptomatic individuals and Trucheck – Femmesafe for Annual women’s cancer screening testing.


The No Risk Blood Based Biopsy

  • To triage symptomatic individuals who have been advised an invasive tissue biopsy to check for malignancy
  • Patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations
  • Suspected metastatic relapse to rule out a new primary

Post-Diagnosis Services

Deep Genomic Analysis of Tumor on a FFPE block identifies SNVs | INDELs | CNAs | Fusions | TMB | PDL1 | MSI | HRR


CellDx™ is a comprehensive test to analyse actionable therapy options using guideline recommended genes in solid tumors.


What is Deep Genomic Analysis ?

Deep genomic analysis is a method of detecting the four main classes of modifications known to drive cancer growth: base substitutions, insertions and deletions, copy number alterations (CNAs), and fusions. This test can be done on FFPE tissue, peripheral whole blood, bone marrow aspirate, or extracted nucleic acid, among other specimen types. When compared to traditional molecular testing, deep genomic analysis helps you better anticipate response or resistance to targeted and immunotherapies for more advanced cancer patients.


The Advantage of CellDx™
Based on the particular genomic profile of each patient’s cancer, CellDx is designed to offer physicians with clinically meaningful information — both to select appropriate therapy for patients and to comprehend results with evidence of resistance.


Exacta® can identify the most efficacious drugs for every individual cancer. Exacta® analysis is available on a Blood and/or Tissue sample.


Exacta® is a multi-analyte and multi-coordinate investigation that integrates genomic analysis to cover alterations in >592 genes and perturbations in the expressions of >20,000 genes to unravel actionable mutations and pathways propelling an individual patient’s cancer.


Monitor cancer or its recurrence or changes in the tumor characteristics through a simple blood test….


Keeping track of cancer is very critical

Cancer is best managed by a treatment plan that stays one step ahead of the tumor. Conventional techniques such as imaging or scans could take more than 3 months to detect the effectiveness of treatments. It is important to determine as quickly as possible if the cancer is responding to the therapy or is progressing.


Cancertrack™ is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. Cancertrack™ can be used to monitor the disease / recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anaesthesia or painful surgical biopsies.


Features of Cancertrack™

  • Multi-coordinate and multi-dimensional probes to track down DNA and RNA released by cancer cells in the patient’s blood
  • Unique, unprecedented capability to detect cancerous activity
  • Enables real-time, rapid response to the dynamic molecular profile of a patient’s cancer
  • Safe, accurate, simple, and cost-effective
  • Non-invasive blood test
    Not dependent on the availability of tissue
  • Tests all active disease sites
  • Limit of detection is 0.1% Mutal Allele Frequency
  • For more powerful than conventional biopsy
  • Extensive coverage of NCCN recommended biomarkers

Cancertrack™ is suitable for
Every person who has been diagnosed with cancer; as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumor DNA and RNA before the initiation of therapy.

Tests at a Glance

Test and Screening Prices​

Test price guide is contained below. Please note that our Consultant Practitioner shall confirm the price and test type prior to booking.

All tests are required to be paid in advance of the test being conducted. 

Frequently Asked Questions

No. However, your healthcare provider can advise if Trucheck™ is suitable for you to use alongside standard care screening options.

Yes. A healthcare provider must approve and prescribe a Trucheck™ test for you.

No. In these circumstances, you should seek urgent medical advice.

Trucheck™ Intelli checks for more than 70 solid tumour based cancers. 

Clinical trials have demonstrated the effectiveness of Trucheck™ when used as an annual test. Therefore, we recommend you take the test on a yearly basis.

Trucheck™ can help people without symptoms, who have a higher cancer risk, due to family history or age. You can ask your healthcare provider if Trucheck™ is suitable for you.

Trublood® is ultrasensitive detection of circulating tumor cells by  immunocytochemistry (ICC) staining to identify specific subtype.

Circulating Tumor Cell (CTC) test involves only enumeration of CTCs. In Trublood® the initial isolation/harvesting of CTCs is done by specialized proprietary method which helps to isolate maximum number of CTCs followed by their in vitro expansion to amass enough CTCs for further testing. Following this, the CTCs are stained with specific ICC based antibodies to identify histopathological subtype.

Trublood ® detects presence of carcinoma i.e. epithelial malignancies. It does not detect haematolymphoid malignancies. Carcinomas are the most common malignancy in adults.

Yes, it can most often differentiate between common subtypes such as adenocarcinoma vs squamous cell carcinoma.

Trublood® can distinguish common subtypes such as adenocarcinoma vs squamous cell carcinoma vs neuroendocrine tumors. However, classification into some rare subtypes of epithelial malignancies is currently not feasible with Trublood®.
Trublood® focuses on detection of epithelial malignancy and its subtyping. It does not detect grade of the tumor.
Trublood® and CTC ‘enumeration’ are two different solutions with different purpose. Trublood® is for detection of carcinoma in a patient with specific symptoms or cancer associated signs (e.g. suspicious lesion on radiology). Trublood® does not provide CTC enumeration and hence is not intended as a baseline for future cancer monitoring of a Trublood® positive patient.
Trublood® validation cohort did not include carcinoma in situ cases. However, literature records detection of CTCs in carcinoma in situ cases.
Trublood® validation cohort included both non-metastatic (early stage) and metastatic cancers and overall sensitivity was found to be 94.6%.

Trublood® is not a cancer screening test. It is meant for detection of cancer in a suspected patient with either signs or symptoms suggestive of a particular organ involvement.

Trublood® has been validated for cancer patients suspected with a specific organ involvement e.g. female with complex ovarian cyst on USG of abdomen. The specificity and sensitivity of Trublood® pertains to such organ specific detection of cancer. It is currently not offered to patients without clinical suspicion of a particular organ involvement.

Peripheral venous blood is collected for Trublood® test. Even though the method of blood draw is similar to any routine pathology test, Trublood® requires sample to be collected, stored and transported as per specific instructions provided in Trublood® kit.

The sample is transported in temperature-controlled boxes.

Consultation with the treating physician to undertake further clinical investigations is advised.

Trublood® test has been validated and reports objective findings based on immunocytochemistry of circulating tumor cells. It is a very specific test with statistically insignificant chance of a false positive. However, decision for confirmation of presence of malignancy is to be taken by the treating physician, if so desired.

Follow up Trublood® testing after a month and consultation with your treating physician to decide future course is advised.

Trublood® cannot be offered to individuals less than 18 years of age, as it has been validated in adults over 18 years of age.

Trublood® is a non-invasive alternative to tissue biopsy which informs about presence or absence of cancer and if cancer is present, its histopathological subtype. Additional testing for relevant theragnostic markers can also be availed in Trublood®. Thus, suspected patients can obtain this information without a tissue biopsy.

Trublood® cannot detect certain mesenchymal or haematolymphoid malignancies. Certain rare subtypes of carcinomas cannot be distinguished/detected with Trublood®.

Positive result of the Trublood® test is a decision support tool for the treating clinician and it is the discretion of each doctor to decide the sufficiency of evidence to accept diagnosis and for starting a particular regimen of treatment. Further, doctors take into consideration all the relevant information and test results for an individual patient and the weight to be given to each input will therefore depend upon the clinician’s judgment in each case.

Exacta® is a comprehensive analysis wherein the samples submitted by the patient (e.g., fresh tissue, FFPE blocks, blood, fluids) are analysed in a 360 degree manner – the DNA, RNA, drug efficacies and suitability, the drug pathways etc, to come up with the most suited drug options for that particular patient. It is a patient-specific recommendation of drugs and drug combinations with a higher potential for success. The selected treatment must be administered only under the supervision of the treating oncologist.

Cancers can be very aggressive and may evolve rapidly, and the tumour profile can change dramatically over time. Starting the treatment immediately is essential as it is the best strategy to counter the aggressiveness of cancer. If there is a long enough delay, cancer may gain resistance to treatments, and re-analysis may be required.

The therapy recommendation will include only those drugs which have been approved by the FDA for use – in a patient’s cancer type or any cancer type, as well as those drugs that are used to treat non-cancerous conditions. Investigational anti-cancer drugs will never be suggested.

Liquid biopsy permits real-time high-frequency monitoring of disease status and response to treatment. It effectively identifies signs of recurrence or emergent chemoresistance, as well as newer vulnerabilities of the tumor. This information empowers the treating clinician to make appropriate therapeutic course corrections in real-time to benefit the quality of life plus overall and progression-free survival.

The rapid and continuous evolution of the molecular profile of tumors results in tumor heterogeneity, which confers significant survival benefits on the tumor. Cancertrack unravels these molecular features in real-time to identify critical signs linked to recurrence or emerging drug resistance and novel vulnerabilities, which can help the treating clinician to avail optimum treatments to intercept such cancers in a timely manner.

Cancertrack should ideally be performed at every important milestone in the fight against cancer and especially when the tumor has disappeared from the conventional imaging/patient is under follow-up for recurrence monitoring.

While Cancertrack is extremely robust and multi-dimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.